Injection Training With Omnitrope 

Patients and caregivers who will administer Omnitrope should receive training and instruction on the proper use of Omnitrope. Patients should review the full Prescribing Information and Instructions for Use. Patients should ask their healthcare professional about anything they do not understand.

  • Available in 5 mg and 10 mg
  • Flexible dosing provides a broad injection range for patients
  • Ready-to-use liquid cartridge eliminates the need to reconstitute
  • Liquid cartridge remains stable for 28 days after first injection*
    • Preservatives: phenol (10 mg) and benzyl alcohol (5 mg)
  • One-time priming upon insertion of new cartridge

The Omnitrope Pen is covered by a 2-year guarantee for defective materials or workmanship. If the pen breaks or is not working properly, patients can call their OmniSource Patient Support Specialist for a new one at 877.456.6794 (Mon – Fri, 8AM – 8PM ET).

*Cartridge must be stored or refrigerated from 36°F to 46°F.

Injection Training With the Omnitrope Vial & Syringe

  • Each 5.8 mg vial of Omnitrope is matched with a 1.14 mL vial of bacteriostatic water (preserved with benzyl alcohol) for reconstitution
  • Three-week stability once reconstituted

To further assist with the Omnitrope injection process, you may download this
convenient Omnitrope Administration Guide and print it for reference:

Omnitrope Administration Guide

1. Omnitrope [package insert]. Princeton, NJ: Sandoz Inc; 2016.


Omnitrope is a recombinant human growth hormone indicated for:

  • Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi Syndrome, Small for Gestational Age, Turner Syndrome, and Idiopathic Short Stature
  • Adult: Treatment of adults with either adult onset or childhood onset GHD



  • Acute Critical Illness: Somatropin should not be used to treat patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure
  • Prader-Willi Syndrome in Children: Somatropin should not be used in patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients
  • Active Malignancy: Somatropin is contraindicated in patients with any evidence of active malignancy. Growth hormone deficiency may be an early sign of a pituitary tumor or other intracranial tumor; the presence of such a tumor should be excluded before initiation of somatropin treatment
  • Hypersensitivity: Omnitrope® is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients. Systemic hypersensitivity reactions have been reported with postmarketing use of somatropin products
  • Diabetic Retinopathy: Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy
  • Closed Epiphyses: Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses


  • Acute Critical Illness: Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic doses of somatropin
  • Prader-Willi Syndrome in Children: There have been reports of fatalities after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Patients with Prader-Willi syndrome should be evaluated for signs of upper airway obstruction and sleep apnea before initiation of treatment with somatropin. If, during treatment with somatropin, patients show signs of upper airway obstruction (including onset of or increased snoring) and/or new onset sleep apnea, treatment should be interrupted
  • Neoplasms: An increased risk of a second neoplasm has been reported for childhood cancer survivors treated with somatropin for GH deficiency that developed following radiation to the brain/head. Intracranial tumors, in particular meningiomas, were the most common of these. The relationship between somatropin therapy and CNS tumor recurrence in adults is unknown. Monitor for progression or recurrence in patients receiving somatropin therapy who have a history of GH deficiency secondary to an intracranial neoplasm. Thoroughly consider the risks and benefits of starting somatropin in children at increased risk for developing malignancies due to certain rare genetic causes of short stature. These patients should be carefully monitored for development of neoplasms. Any pre-existing nevi should be monitored carefully for increased growth or potential malignant changes
  • Impaired Glucose Intolerance and Diabetes Mellitus: Previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be unmasked during somatropin treatment. New-onset type 2 diabetes mellitus has been reported. As a result, blood glucose concentrations should be monitored periodically in all patients taking somatropin, especially in those with risk factors for diabetes mellitus. Patients with pre-existing type 1 or type 2 diabetes mellitus or impaired glucose tolerance should be monitored closely during somatropin treatment

Show more....